-- Gan & Lee Pharmaceuticals (SHA:603087) received approval from China's National Medical Products Administration for the clinical trials of GLR1062 injection, according to a Shanghai bourse filing on Thursday.
The drug will be tested for the treatment of neovascular (wet) age-related macular degeneration in adults.